Registry of CytoSorb Therapy in COVID-19 ICU Patients (CTC REGISTRY)

Overview

About this study

The study aims to contribute patient-level clinical data to the Registry of CytoSorb® Therapy In COVID-19 ICU Patients (CTC REGISTRY). Registry of patient-level clinical data on CytoSorb hemoadsorption provided via integration of the CytoSorb® device into CRRT or hemoperfusion extracorporeal circuits in COVID-19 ICU patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:


1. Confirmed COVID-19.

2. Provision of CytoSorb therapy per Instructions for Use (IFU) of the CytoSorb device.

Exclusion Criteria:

1. CytoSorb therapy for diseases other than COVID-19.

2. Survival unlikely within 24 hours (for prospectively enrolled patients).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/17/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Kai Singbartl

Closed for enrollment

Contact information:

Kai Singbartl

(480) 342-1376

Singbartl.Kai@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20597059

Mayo Clinic Footer